Contact us

Oligonucleotides CDMO Companies
Oligonucleotides Contract Manufacturing Services

Your Trusted Partners for Oligonucleotides Contract Manufacturing and Development

Showing 9 facilities
Sylentis
Spain

Sylentis

Sylentis

Oligonucleotide manufacturer.

BATCH SIZE: Small, Medium, Large

COMPLIANCE: EMA (EU GMP), World Health Organization (GMP / HACCP), FDA (cGMP), ISO, ICH

REGION: Europe

USE: Human, Veterinary

SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Quality Assurance services

CATEGORY / PRODUCT: OLIGONUCLEOTIDES

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

MARKETS: FDA (USA), EMA (EU)

CARBOGEN AMCIS | Shanghai, China
China

CARBOGEN AMCIS | Shanghai, China

CARBOGEN AMCIS

Large scale manufacturing.

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (B) Blood and blood forming organs, (V06) Nutrients

CATEGORY / PRODUCT: SERVICES, OLIGONUCLEOTIDES, CHEMICAL-SYNTHETIC

USE: Human

COMPLIANCE: ANVISA (Brazil B-GMP), NMPA (China GMP)

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

Limited view

FDF / DRUG PRODUCTS manufacturing site

MAI network supplier

An USFDA approved API & Intermediate Manufacturing facility.

Location available after registration

Limited view

SERVICES manufacturing site

MAI network supplier

Polpharma API is a European CDMO offering small-molecule, oligonucleotide, and payload-linker for ADC development and manufacturing

Location available after registration

Limited view

FDF / DRUG PRODUCTS manufacturing site

MAI network supplier

One-stop CDMO Solutions for APl and Key intermediates.

Location available after registration

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+4 more facilities

Create free account

Oligonucleotide-based therapies are revolutionizing the treatment of genetic diseases, cancers, and rare disorders. These short DNA or RNA sequences require complex chemistry, precise manufacturing, and strict regulatory compliance — making oligonucleotides CDMO companies essential for biotech and pharma developers.

Specialized oligonucleotides contract manufacturing partners provide the infrastructure, technical know-how, and quality systems necessary to produce antisense oligonucleotides (ASOs), siRNAs, aptamers, and other advanced nucleic acid-based therapeutics at clinical and commercial scale.

How to Choose Oligonucleotides CDMO Companies

Not all CDMOs are prepared for the unique challenges of oligonucleotide synthesis and purification. When evaluating oligonucleotides CDMO companies, key criteria include:

  • Synthetic capability: Can they produce phosphorothioate, gapmer, or LNA-modified oligos?
  • Scalability: Do they offer gram-to-multi-kilogram scale synthesis suitable for clinical and commercial needs?
  • Purification technologies: Expertise in HPLC, ion exchange, and ultrafiltration specifically for oligos
  • Analytical rigor: Ability to test identity, purity, sequence fidelity, and residual solvents
  • GMP readiness: Do they support GMP manufacturing and regulatory documentation for global filings?
  • Experience with delivery formats: LNP-formulated, PEGylated, or conjugated oligonucleotides

Choosing a CDMO with deep oligo-specific expertise ensures smoother development, fewer surprises, and a faster path to patients.

Key Services Offered by Oligonucleotides Contract Manufacturers

Trusted oligonucleotides contract manufacturing partners typically offer:

  • Solid-phase synthesis of DNA, RNA, and chemically modified oligos
  • Process development and optimization for yield, purity, and cost efficiency
  • Purification and desalting using ion-exchange, reverse-phase, and size-exclusion chromatography
  • Conjugation with lipids, peptides, or GalNAc moieties for targeted delivery
  • LNP formulation and sterile filtration for injectable formats
  • GMP manufacturing for Phase I–III and commercial batches
  • Analytical testing: LC-MS, UV spectroscopy, CE, and endotoxin testing
  • CMC documentation and regulatory support for oligonucleotide submissions

These services are designed to meet the technical and regulatory demands of modern nucleic acid therapeutics.

Advantages of Partnering with Oligonucleotides CDMO Companies

Working with leading oligonucleotides CDMO companies offers strategic advantages:

  • Faster development timelines with proven oligo synthesis platforms
  • High purity and reproducibility through validated, scale-ready processes
  • Cost-efficiency via integrated synthesis, purification, and analytics
  • Regulatory compliance across EU, US, and Asian markets
  • Innovative capabilities for custom chemistries and targeted delivery approaches

These benefits are critical in the race to advance oligo-based treatments from concept to clinic.

Oligonucleotides CDMO Companies

  • Sylentis: Sylentis is a leading CDMO in therapeutic oligonucleotides, specializing in GMP manufacturing and comprehensive support from development to commercialization. [See CDMO profile]
  • Ascendia Pharmaceutical Solutions: GMP-certified CDMO for advanced sterile and non-sterile pharmaceutical manufacturing, formulation development, and analytical testing. [See CDMO profile]
  • Lukas Heil-Betriebsstätte: High-performance production facility that complies with the latest GMP standards for sterile and aseptic liquids, particularly glass ampoules. [See CDMO profile]
  • Demo facility: Tissue therapy, Cell therapy and GTMP (Gene Therapy). [See CDMO profile]

Related Information

Let MAI CDMO Network Help You Find the Right Oligonucleotides CDMO Partner

At MAI CDMO Network, we specialize in helping biopharma companies connect with experienced oligonucleotides CDMO companies that fit your synthesis, scale, and regulatory needs. Whether you’re developing an ASO, siRNA, or innovative nucleic acid conjugate, our network of oligonucleotides contract manufacturing experts will help bring your molecule to market faster.

Looking for a trusted oligo manufacturing partner? Contact us today and find your perfect CDMO match.